Flagship is the ideal partner when you need to establish commercial differentiation by:
- Designing, evaluating, and implementing a prototype diagnostic strategy in a regulated space, to
- Accelerate development and increase the probability of diagnostic success through confident decision making.
Flagship creates novel diagnostic approaches by:
- Integrating our technology into existing IHC based CDx formats, which requires only the addition of our software.
- Utilizing our in-house Quality Management System (QMS), which is in compliance with ISO13485, ISO14971, IEC62304 and FDA 21 CFR Part 820 QSR.
Flagship’s cTA® platform has 7 granted patents and over 19 patents pending.
We are very pleased to work with Flagship’s image analysis with mRNA ISH, which is particularly important for the development of companion diagnostics.